Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 2/20 | 0.42 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.42 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.42 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | XDH | P47989 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
| ▸ | GDA | Q9Y2T3 | 2/20 | 0.38 |
| ▸ | AKT2 | P31751 | 2/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | APEX1 | P27695 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mercaptopurine Anhydrous SCHEMBL5545602 | 0.73 | — | — | |
| SCHEMBL5612970 | 0.70 | GDA (0.36) | GDAPDPK1KDM4EALDH1A1 | |
| 2,6-Diaminopurine SCHEMBL2953673 | 0.67 | NUDT1 (0.34) | PI4KAPI4K2BPI4K2API4KBDYRK1A | |
| SCHEMBL5173516 | 0.64 | — | — | |
| Adenine SCHEMBL3892039 | 0.64 | PI4KA (0.38) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| SCHEMBL5612935 | 0.63 | GDA (0.34) | LMNAGDAPDPK1KDM4EMAPT | |
| SCHEMBL1747899 | 0.62 | KDM4A (0.37) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| SCHEMBL11463894 | 0.62 | — | — | |
| SCHEMBL597417 | 0.61 | GDA (0.35) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| Adenine SCHEMBL3416954 | 0.60 | PI4KA (0.48) | PI4KAPI4K2BPI4K2API4KBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118043034-A | Keli imidazole formulations | 艾匹真尼克斯治疗公司 | 2024-05-14 | — | — | CN | claimed |
| CN-110612119-A | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents | 西雅图儿童医院（DBA西雅图儿童研究所） | 2019-12-24 | — | — | CN | claimed |
| EP-3157920-B1 | INDOLIZINE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARM SPA (IT) | 2019-08-07 | — | — | EP | claimed |
| WO-2018148224-A1 | PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS | Seattle Children's Hospital (dba Seattle Children's Research Institute) (US) | 2018-08-16 | — | — | WO | claimed |
| US-12576085-B2 | Combination comprising an ATP analog and an adenosine receptor antagonist or a nucleobase/nucleoside analog for the treatment of cancer | SAWYER MICHAEL BRUCE (CA) | 2026-03-17 | — | — | US | disclosed |
| US-12358868-B2 | Chemical derivatives and methods for synthesizing and compounding chemical derivatives related to capsaicin palmitate and capsaicin prodrugs | CHORDA PHARMA, INC. (US) | 2025-07-15 | — | — | US | disclosed |
| CN-118206555-B | 3, 8-Disubstituted adenine derivative, preparation method and application thereof | 海赋药业(海南)有限责任公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-110612119-B | Phosphatidylether (PLE) CAR T cell tumor targeting (CTCT) agents | 西雅图儿童医院（DBA西雅图儿童研究所） | 2024-10-29 | — | — | CN | disclosed |
| US-20240226160-A9 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2024-07-11 | — | — | US | disclosed |
| CN-118206555-A | 3, 8-Disubstituted adenine derivative, preparation method and application thereof | 海赋药业(海南)有限责任公司 | 2024-06-18 | — | — | CN | disclosed |
| US-20240131072-A1 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2024-04-25 | — | — | US | disclosed |
| CN-117897490-A | Recombinant yeast cells | 丹尼斯科美国公司 | 2024-04-16 | — | — | CN | disclosed |
| WO-2018148224-A1 | PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS | Seattle Children's Hospital (dba Seattle Children's Research Institute) (US) | 2018-08-16 | — | — | WO | disclosed |
| US-20180050147-A1 | HEMODIALYSIS DEVICE | SHIH HSIEN CHANG (TW) | 2018-02-22 | — | — | US | disclosed |
| CN-101490052-B | Therapeutic compounds and their use in cancer | MYRIAD GENETICS INC | 2012-08-08 | — | — | CN | disclosed |
| CN-102617596-A | Dimeric sesquiterpene compound Hippolide I, its preparation method and its purpose | SHANGHAI CHANGZHENG HOSPITAL | 2012-08-01 | — | — | CN | disclosed |
| CN-102617526-A | Dimeric sesquiterpene compound Hippolide J, its preparation method and its purpose | SHANGHAI CHANGZHENG HOSPITAL | 2012-08-01 | — | — | CN | disclosed |
| CN-102603689-A | Norditerpenoid compound Lachnin A, and preparation method and application thereof | SHANGHAI CHANGZHENG HOSPITAL | 2012-07-25 | — | — | CN | disclosed |
| US-20070142317-A1 | Topical composition for treatment of skin disorders | QLT USA, INC. (US) | 2007-06-21 | — | — | US | disclosed |
| WO-2005065668-A2 | TOPICAL COMPOSITIONS COMPRISING HALO-DEOXYADENOSINES FOR TREATMENT OF SKIN DISORDERS | QLT USA, INC. (US) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142317-A1 | Topical composition for treatment of skin disorders | CDA, ADA, DCTD | PI4KA 3462/4885PI4K2B 3646/4885PI4K2A 2619/4885 |
| US-12576085-B2 | Combination comprising an ATP analog and an adenosine receptor antagonist or a nucleobase/nucleoside analog for the treatment of cancer | ADORA2A, ADORA2B, ABCG2 | PI4KA 629/4885PI4K2B 564/4885PI4K2A 811/4885 |
| US-12358868-B2 | Chemical derivatives and methods for synthesizing and compounding chemical derivatives related to capsaicin palmitate and capsaicin prodrugs | HCAR2, HCAR3, TRPV1 | PI4KA 3587/4885PI4K2B 3720/4885PI4K2A 3155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.